Zevra Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 10.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 615.22M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical tr...